Genetic Analysis of Lesions Provides Accurate Esophageal Cancer Test
By LabMedica International staff writers Posted on 31 Aug 2016 |
Image: A histopathology showing simple columnar metaplasia of the epithelium of Barrett\'s Esophagus characterized by goblet cell (Photo courtesy of Nephron).
Barrett's Esophagus is a common condition that affects an estimated 1.5 million people in the UK alone, although many are undiagnosed. This condition involves normal cells in the esophagus being replaced by an unusual cell type called Barrett's Esophagus, and is thought to be a consequence of chronic reflux or heartburn.
People with Barrett's have an increased risk of developing esophageal cancer, a neoplasm that has a five year survival of 15% and although the overall lifetime risk of developing esophageal cancer in people with Barrett's is significant, most Barrett's patients will not develop cancer in their lifetime. It is the unfortunate few who will develop an aggressive cancer.
An international team of scientists led by those at the Queen Mary University of London (UK) followed up more than 300 Barrett's patients over three years, and analyzed around 50,000 cells in the process. They performed genetic analysis of individual cells and measured the genetic diversity in each lesion to track it over time. The results validated a previous group's discovery that measurement of the genetic diversity between Barrett's cells in any given lesion is a good predictor of which patients are at high risk of developing cancer. Genetic diversity describes how diverse the genetic make-up of individual cells is in any given group of cells.
In addition, the team found that there were no significant changes in genetic diversity during the three years that the patients were followed. Clonal expansions are rare, being detected once every 36.8 patient years, and growing at an average rate of 1.58 cm2 per year, often involving the p16 locus. This suggests that the genetic diversity amongst a person's Barrett's cells is essentially fixed over time, and mutations have little impact on the lesion's development. Whenever someone's Barrett's is tested, their future risk can be predicted regardless of how soon it is after the appearance of abnormal cells.
Trevor A. Graham PhD, a lecturer in Tumor Biology and senior author of the study said, “Our findings are important because they imply that a person's risk of developing esophageal cancer is fixed over time. In other words, we can predict from the outset which Barrett's patients fall into a high risk group of developing cancer and that risk does not change thereafter.” The study was published on August 19, 2016, in the journal Nature Communications.
Related Links:
Queen Mary University of London
People with Barrett's have an increased risk of developing esophageal cancer, a neoplasm that has a five year survival of 15% and although the overall lifetime risk of developing esophageal cancer in people with Barrett's is significant, most Barrett's patients will not develop cancer in their lifetime. It is the unfortunate few who will develop an aggressive cancer.
An international team of scientists led by those at the Queen Mary University of London (UK) followed up more than 300 Barrett's patients over three years, and analyzed around 50,000 cells in the process. They performed genetic analysis of individual cells and measured the genetic diversity in each lesion to track it over time. The results validated a previous group's discovery that measurement of the genetic diversity between Barrett's cells in any given lesion is a good predictor of which patients are at high risk of developing cancer. Genetic diversity describes how diverse the genetic make-up of individual cells is in any given group of cells.
In addition, the team found that there were no significant changes in genetic diversity during the three years that the patients were followed. Clonal expansions are rare, being detected once every 36.8 patient years, and growing at an average rate of 1.58 cm2 per year, often involving the p16 locus. This suggests that the genetic diversity amongst a person's Barrett's cells is essentially fixed over time, and mutations have little impact on the lesion's development. Whenever someone's Barrett's is tested, their future risk can be predicted regardless of how soon it is after the appearance of abnormal cells.
Trevor A. Graham PhD, a lecturer in Tumor Biology and senior author of the study said, “Our findings are important because they imply that a person's risk of developing esophageal cancer is fixed over time. In other words, we can predict from the outset which Barrett's patients fall into a high risk group of developing cancer and that risk does not change thereafter.” The study was published on August 19, 2016, in the journal Nature Communications.
Related Links:
Queen Mary University of London
Latest Molecular Diagnostics News
- Novel Method Combining Nano Informatics and AI Paves Way for Cancer Blood Tests
- Groundbreaking Molecular Diagnostic Kit to Provide Lyme Disease Detection in Minutes
- New Assay Detects Heart Failure Biomarker in Less than 11 Minutes
- Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury
- New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant
- Novel Technique Detects Biomarkers for Kidney Diseases with Nephritic Syndrome
- Lipoprotein Blood Test Detects Hereditary Cardiovascular Risk
- Whole Genome Sequencing Detects Infection Transmission in NICU
- Novel Inexpensive, Shelf-Stable, Easy To Use Tests Bring Lab-Level Precision at POC
- World’s First One-Minute Hepatitis C Antibody Test Facilitates Quick Triage
- Game-Changing Blood Test for Stroke Detection Could Bring Life-Saving Care to Patients
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections